We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
-14.51%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.25B
AUM Growth
-$409M
Cap. Flow
-$106M
Cap. Flow %
-8.49%
Top 10 Hldgs %
50.14%
Holding
212
New
40
Increased
31
Reduced
43
Closed
54

Top Buys

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$43.5M
2
RGNX icon
Regenxbio
RGNX
+$19.9M
3
ARAV
Aravive, Inc. Common Stock
ARAV
+$15.6M
4
ZYNE
Zynerba Pharmaceuticals, Inc
ZYNE
+$14.2M
5
LJPC
La Jolla Pharmaceutical Company
LJPC
+$12.7M

Top Sells

Rank Stock Value
1
ZSPH
ZS PHARMA INC COMS TK (DE)
ZSPH
+$19M
2
AGN
Allergan plc
AGN
+$18M
3
ANIP icon
ANI Pharmaceuticals
ANIP
+$17.5M
4
CBPO
China Biologic Products Holdings, Inc.
CBPO
+$17M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$16.5M

Sector Composition

Rank Sector Weight
1 Healthcare 80.82%
2 Miscellaneous 18.47%
3 Consumer Staples 0.59%
4 Consumer Discretionary 0.07%
5 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CAPR icon
151
Capricor Therapeutics
CAPR
$498M
$16K ﹤0.01%
400
– –
NUVA
152
DELISTED
NuVasive, Inc.
NUVA
$12K ﹤0.01%
+252
New +$13K
XBI icon
153
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$6K ﹤0.01%
+100
New +$7.88K
ACGN
154
DELISTED
Aceragen Inc
ACGN
$5K ﹤0.01%
+1
New +$3.54K
HSTO
155
DELISTED
Histogen Inc. Common Stock
HSTO
$2K ﹤0.01%
2
-498
-100% -$454K
ASND icon
156
Ascendis Pharma A/S
ASND
$15.8B
– –
-10,000
Closed -$176K
CHRS icon
157
Coherus Oncology
CHRS
$205M
– –
-258,716
Closed -$7.48M
CNMD icon
158
CONMED
CNMD
$1.41B
– –
-8,554
Closed -$498K
CYH icon
159
Community Health Systems
CYH
$419M
– –
-4,813
Closed -$250K
DHR icon
160
Danaher
DHR
$147B
– –
-14,878
Closed -$856K
ENTA icon
161
Enanta Pharmaceuticals
ENTA
$358M
– –
-4,956
Closed -$223K
ESPR
162
CALL
DELISTED
Esperion Therapeutics
ESPR
– –
-200,000
Closed -$16.4M
LKFT
163
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.83B
– –
-20,000
Closed -$1.03M
HRTX icon
164
Heron Therapeutics
HRTX
$59.6M
– –
-448,000
Closed -$14M
ILMN icon
165
Illumina
ILMN
$33.6B
– –
-25,700
Closed -$5.46M
IMUX icon
166
PUT
Immunic
IMUX
$141M
– –
-750
Closed -$6.33M
INCY icon
167
Incyte
INCY
$24.7B
– –
-15,000
Closed -$1.56M
INSM icon
168
Insmed
INSM
$26.2B
– –
-285,812
Closed -$6.98M
LMAT icon
169
LeMaitre Vascular
LMAT
$1.84B
– –
-19,838
Closed -$239K
MCK icon
170
McKesson
MCK
$105B
– –
-1,015
Closed -$228K
MCRB icon
171
Seres Therapeutics
MCRB
$46.2M
– –
-2,500
Closed -$2.08M
MGNX icon
172
MacroGenics
MGNX
$257M
– –
-76,208
Closed -$2.89M
NKTR icon
173
Nektar Therapeutics
NKTR
$2.28B
– –
-22,333
Closed -$4.19M
PAHC icon
174
Phibro Animal Health
PAHC
$1.42B
– –
-6,809
Closed -$265K
PBYI icon
175
CALL
Puma Biotechnology
PBYI
$477M
– –
-100,000
Closed -$11.7M
5 6
7
8 9

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q3 2015 Portfolio in Review

As of Q3 2015, Perceptive Advisors held 212 positions worth $1.25B, down 25% from $1.66B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Perceptive Advisors withdrew a net $106M in Q3 2015, closing 54 positions and reducing 43 holdings. Its most notable exit was ZS PHARMA INC COMS TK (DE), an estimated $19M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 82% a quarter earlier, followed by Miscellaneous and Consumer Staples.

Against the trend, Perceptive Advisors opened a new position in Global Blood Therapeutics, Inc. worth $38.9M.

  • Perceptive Advisors's largest Q3 2015 buy was Global Blood Therapeutics, Inc.: 921,800 shares worth $38.9M.
  • Perceptive Advisors added most to Aravive, Inc. Common Stock in Q3 2015, an estimated $15.6M increase.
  • Perceptive Advisors's biggest Q3 2015 reduction was ANI Pharmaceuticals, cutting an estimated $17.5M.
  • Perceptive Advisors fully exited ZS PHARMA INC COMS TK (DE) in Q3 2015, selling an estimated $19M.
  • Perceptive Advisors's ten largest holdings make up 50% of its $1.25B portfolio in Q3 2015.
  • Perceptive Advisors opened 40 new positions and closed 54 in Q3 2015.
  • Perceptive Advisors's portfolio value fell 25% quarter-over-quarter to $1.25B.

Based on Perceptive Advisors's 13F filing for Q3 2015, filed 16 Nov 2015.